Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management - Global
- Beta
- 0.70
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
SLIMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
23-48.15%Social Signal Score
Mentions (17)
- Newsbenzinga.com·5d ago·Negative
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss Novo Nordisk A/S (NYSE:NVO) on Wednesday revealed new clinical and real-world data at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, showcasing the efficacy of its next-generation weight-loss treatments.
View source ↗ - Newsmarketbeat.com·12d ago·Positive
Viking's Obesity Edge May Be Staying Power, Not Weight Loss Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
View source ↗ - News247wallst.com·13d ago·Neutral
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals
View source ↗ - Newsbenzinga.com·14d ago·Negative
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing Viking Therapeutics Inc. (NASDAQ:VKTX) stock surged on Tuesday after the company released positive topline results from its much-anticipated VK2735 maintenance trial.
View source ↗ - News247wallst.com·17d ago·Neutral
Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation? Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
View source ↗ - News247wallst.com·20d ago·Negative
Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption A landmark trial just proved semaglutide can pull children as young as six below the obesity threshold, yet Wall Street shrugged and the real battle over who pays, who prescribes, and whether society is ready has barely begun.
View source ↗ - Newsmarketbeat.com·21d ago·Positive
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average body mass index of approximately 37 and 71% of participants being female.
View source ↗ - Newsmarketbeat.com·21d ago·Negative
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss Viking Therapeutics NASDAQ: VKTX said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.
View source ↗ - Newsglobenewswire.com·22d ago·Negative
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile Data support CRB-913's potential to establish a new class of oral non-increti
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
View source ↗ - Newsglobenewswire.com·35d ago·Negative
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination
View source ↗ - Newsglobenewswire.com·43d ago·Negative
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
View source ↗ - Newsfool.com·43d ago·Neutral
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
View source ↗ - Newsmarketbeat.com·50d ago·Neutral
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
View source ↗ - Newsseekingalpha.com·59d ago·Neutral
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion Eli Lilly and Company delivered a monumental Q2 2026, with revenues up 48% to $23 billion, driven by MOUNJARO and ZEPBOUND. I maintain a 'Strong Buy' rating on the company, citing robust double-digit growth in key drugs and successful pipeline expansion, including positive phase 3 retatrutide data. EBGLYSS achieved 131% YoY sales growth and secured a label expansion, offering the only 6-dose annual mainte
View source ↗
Congress trades
No disclosed congressional trades in SLIM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.